Status:
UNKNOWN
Role of AT1-receptor Blockers in Insulin-induced Vasodilation.
Lead Sponsor:
Maastricht University Medical Center
Conditions:
Hypertension
Insulin Resistance
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
In this study we hypothesize that blocking the angiotensin II AT1-receptor improves the insulin-induced microvascular dilatation. Objectives: 1. Does blockade of the angiotensin II AT1-receptor improv...
Eligibility Criteria
Inclusion
- hypertensive subjects:
- 18-60 years
- Caucasian
- untreated hypertension \>140/90mmHg.
- normotensive subjects:
- 18-60 years
- Caucasian
- Blood pressure \<140/90 mmHg.
Exclusion
- Obesity (BMI\>27kg/m2)
- Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
- Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
- Smoking
- Alcohol use \>4U/day
- Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
- Pregnancy
- Wearing contact lenses
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2009
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00742066
Start Date
March 1 2008
End Date
July 1 2009
Last Update
March 17 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Maastricht
Maastricht, P.O. Box 5800, Netherlands, 6202 AZ